- You can view the full Regeneron Pharmaceuticals Ratings Report.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
- Find other investment ideas from our top rated ETFs lists.
Shares have regained their 50-day moving average and look likely to push higher.
Evercore ISI analyst Josh Schimmer is bullish on biotech.
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
Stock prices are either unfairly dragged down by competitors' earnings news or by Amazon's spread into more businesses, Cramer said.
Game on: Jim Cramer is bullish on Electronic Arts, Activision Blizzard and Take-Two Interactive.